Products
Igovomab Biosimilar Radiolabelled Antibody (MUC16) for Research
Pre-made Igovomab benchmark antibody (Radiolabelled antibody, anti-MUC16 therapeutic antibody, Anti-CA125 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Indium (111In) igovomab (trade name Indimacis-125) was a mouse monoclonal antibody for the diagnosis of ovarian cancer.[citation needed]
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-861-1mg | 1mg | 3090 |
| GMP-Bios-INN-861-10mg | 10mg | |
| GMP-Bios-INN-861-100mg | 100mg | |
| GMP-Bios-INN-861-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Igovomab Biosimilar, Radiolabelled Antibody, Anti-Muc16 Antibody: Anti-CA125 therapeutic antibody |
| INN Name | Igovomab |
| Target | MUC16 |
| Format | Radiolabelled antibody |
| Derivation | Mus musculus |
| Species Reactivity | human |
| CH1 Isotype | F(ab')2 - G1 - nd |
| VD LC | F(ab')2 - G1 - nd |
| Highest_Clin_Trial (Jan '20) | |
| Est. Status | |
| 100% SI Structure | |
| 99% SI Structure | |
| 95-98% SI Structure | |
| Year Proposed | |
| Year Recommended | |
| Companies | CIS Bio international (Bagnols/C France) |
| Conditions Approved | |
| Conditions Active | |
| Conditions Discontinued | |
| Development Tech | 0 |
About target - MUC16
1. Protein Mucin-16
2. Gene MUC16
3. Organism Homo sapiens (Human)
Function
Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces.
Miscellaneous
Antigen that is the basis for a widely used serum assay for the monitoring of patients with ovarian epithelial cancer. Due to lack of sensitivity for stage I disease and lack of specificity, it is of little value in the detection of early ovarian cancer. Due to its similarly elevated levels in some nonmalignant conditions, it is not specific enough to be used for population screening.
